Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute	for form 1449A/PT	то		Complete if Known			
				Application Number	Unassigned		
INFO	RMATION	I DISCL	OSURE	Filing Oate	June 12, 2006		
STATEMENT BY APPLICANT				First Named Inventor	Dirk FINSINGER et al.		
• • • • • • • • • • • • • • • • • • • •				Group Art Unit	Unassigned		
	(use as many sl	heets as nec	essary)	Examiner Name	Unassigned		
Sheet	1	of	2	Attorney Docket Number	MERCK-3171		

			U.S. PA	TENT DOCUMENTS	<u></u>
	<u> </u>	U.S. Patent Document			Date of Publication of Cited Occumen
Examiner Initials *	Cite No.1	Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	MM-DD-YYYY
/D O /	1	5354762			October 11, 1994
/D.O./	2	2003207914			November 6, 2003
/D.O./_	3 .	2001011136			August 2, 2001
			-		

		Foreign Patent Document					Pages, Columns, Lines, Where	
Examiner Initials*	Cite No.1	Office ³	Number ⁴	Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Relevant Passages	Τ*
/D.O./	5	wo	2004085399		Merck Patent GmbH	October 7, 2004		
1	6	wo	2004037789		Merck Patent GmbH	May 6, 2004		
	7	wo	2004019941		Merck Patent GmbH	March 11, 2004		
	8	EP	0253468		Rohm and Haas Company	January 20, 1998		Equv to cite
	9	wo	02085857		Bayer Corporation	October 31, 2002		Equv to cite 2
	10	wo	9324468		CIBA-GEIGY AG	December 9, 1993		
	· 11	wo	03037864		Japan Tobacco Inc.	May 8, 2003		
. .	12	wo	0042012		Bayer Corporation	July 20, 2000		Equv to cite 3

Examiner Signature	/David O Dell/	Date Considered	12/04/2007

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will very depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB combol number

Substitute for form 1449A/PTO Complete if Known **Application Number** Unassigned INFORMATION DISCLOSURE Filing Date June 12, 2006 STATEMENT BY APPLICANT First Named Inventor Dirk FINSINGER et al. Unassigned **Group Art Unit** (use as many sheets as necessary) Unassigned **Examiner Name** Attomey Docket Number MERCK-3171 of Sheet

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No.1	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т2		
/D.O.	13	SMITH R A ET AL: "DISCOVERY OF HETEROCYCLIC UREAS AS A NEW CLASS OF RAF KINASE INHIBITORS: IDENTIFICATION OF A SECOND GENERATION LEAD BY A COMBINATORIAL CHEMISTRY APPORACH" BIOORGANIC & MEDICNAL CHEMISTRY LETTERS, OXFORD, GB vol. 11, no. 20, 2001, pages 2775-2778, XP001118699			
/D.O.	14	JOSHI, NAILESH ET AL: "ARYLAMIDES. PARTS V: N'-P-(2,4-DIMETHYOXY-S-TRIAZIN-6-YLAMINOBE NOZOYL)-N2-SUBSTITUTED BENZOYL HYDRAZINES" JOURNAL OF THE INSTITUTION OF CHEMISTS (INDIA), 64(3), 105-6 CODEN: JOICA7; ISSN: 0020-3254, 1992, XP009044479			
		·			
			-		
		·			
_					

_				/
	xaminer ignature	/David O Dell/	Date Considered	12/04/2007

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.